News

A greater decline in lung function prior to treatment start may lead idiopathic pulmonary fibrosis (IPF) patients to stop using Ofev (nintedanib), as might older age, a real-world study from the United Kingdom found. “No predominant reason for discontinuation was identified in this group,” its researchers wrote, but it’s…

Genkyotex’s anti-fibrotic candidate GKT831 appears to be safe and hold therapeutic activity in an ongoing Phase 2 trial in patients with primary biliary cholangitis, an autoimmune-triggered fibrotic disease of the liver. These positive interim results support the development of GKT831 as a possible treatment of other fibrotic diseases,…

BML‐111, a potent activator of the natural anti-inflammatory lipoxin A4 receptor, protects lungs from fibrosis by inhibiting fibroblast activation and decreasing the levels of inflammatory signaling molecules, a mouse study shows. The study “BML-111 suppresses TGF-β1-induced lung fibroblast activation in vitro and decreases experimental pulmonary fibrosis in vivo” was…

Results from the long-term PASSPORT clinical study are consistent with the known safety profile of Esbriet (pirfenidone), further strengthening the safety of the therapy in patients with idiopathic pulmonary fibrosis (IPF). After authorization by the European Medicine Agency (EMA), it was suggested that a large, long-term post-authorization study be conducted…

Galapagos has launched a Phase 2 trial testing the safety and effectiveness of their investigational new therapy called GLPG1205 in patients with idiopathic pulmonary fibrosis (IPF), reporting that the first participant has now received the therapy. GLPG1205 is an anti-inflammatory small molecule that specifically inhibits GPR84, a protein that promotes…

Treatment with Ofev (nintedanib) offers less clinical benefit to patients with severe idiopathic pulmonary fibrosis (IPF) than to those with mild-to-moderate disease, but does improve outcomes if these patients are able to continue on treatment over the longer term, a new study shows. Controlling the therapy’s side effects will be essential…

The incidence of lung cancer is greater among patients with idiopathic pulmonary fibrosis (IPF), compared with the general population, and is associated with a worse prognosis, a new U.S. study reports. The study, “Characteristics of lung cancer among patients with idiopathic pulmonary fibrosis and interstitial lung disease –…

Galecto Biotech is planning a new international Phase 2/3 clinical trial to evaluate inhaled TD139, its investigational candidate for the treatment of patients with idiopathic pulmonary fibrosis (IPF). The design of the study, which will be conducted at several clinical centers across Europe and North America, has already been…

With the U.S. midterm elections now less than two weeks away, patient advocacy groups are solidly focused on a range of hot-button issues, from the Orphan Drug Tax Creditand affordable health insurance to future funding for rare disease research. Yet “whether Democrats take over the House or Senate, or…

East River BioSolutions has received a $224,566 grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) to advance the development of laboratory tools that can aid in the study of idiopathic pulmonary fibrosis (IPF). Development of effective therapies for IPF…